Table 2 Univariable analysis in patients who underwent Abi or Doc therapy.

From: Correction: Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer

  

Abi

Doc

Variables

 

Overall survival

Overall survival

  

HR

95% CI

p

HR

95% CI

p

Age

>72 y.

1.577

0.967–2.571

0.068

1.591

0.929–2.723

0.091

ECOG

>1

5.386

2.566–11.351

<0.001

1.418

0.824–2.439

0.208

Visceral mets.

pos.

1.031

0.443–2.399

0.944

1.474

0.660–3.293

0.344

LN mets.

pos.

1.344

0.719–2.514

0.354

0.796

0.442–1.433

0.446

Bone mets.

pos.

2.426

0.971–6.058

0.058

2.091

0.506–8.643

0.308

Primary local treatment

pos.

0.600

0.369–0.974

0.039

0.996

0.557–1.779

0.988

Primary RPE

pos.

0.804

0.499–1.296

0.370

0.902

0.451–1.804

0.770

Primary RT

pos.

0.729

0.390–1.360

0.321

1.028

0.482–2.189

0.944

PSA median

a

2.529

1.535–4.168

<0.001

0.866

0.505–1.486

0.601

PSA response

present

1.351

0.584–3.126

0.483

0.954

0.474–1.918

0.895

PSA response

>30%

0.600

0.341–1.056

0.076

0.993

0.976–1.011

0.460

PSA response

>50%

0.628

0.379–1.042

0.072

0.973

0.946–1.000

0.054

PSA response

>90%

0.597

0.349–1.020

0.059

0.983

0.852–1.134

0.811

FSCN1 median

a

1.764

1.086–2.866

0.022

0.680

0.394–1.174

0.166

FSCN1 (ROC)

a

2.182

1.336–3.564

0.002

0.733

0.427–1.258

0.260

CTAG1A (median)

>2.285 ng/ml

0.977

0.912–1.047

0.509

-

-

-

KLK2 (median)

>4.088 pg/ml

1.549

0.963–2.493

0.071

-

-

-

  1. Significant values are indicated in bold. LN - Lymph node, RPE – radical prostatectomy, RT – radiation therapy.
  2. aAbi cohort: median (ng/ml): PSA: 66.45, FSCN1: 9.39 /FSCN1 ROC cut-off: 10.22. Doc cohort: median (ng/ml): PSA: 73.69, FSCN1: 5.84 /FSCN1 ROC cut-off: 5.01.
Back to article page